Home
/
Zivo Bioscience, Inc.
/
Financials
/
Quarterly
Zivo Bioscience, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Zivo Bioscience, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$65.6K
Nov 14, 2025
Q2
2025
Jun 30, 2025
$53.4K
Aug 14, 2025
Q1
2025
Mar 31, 2025
$0
May 15, 2025
Q3
2025
Sep 30, 2024
$31.5K
Nov 14, 2025
Q2
2025
Jun 30, 2024
$0
Aug 14, 2025
Q1
2025
Mar 31, 2024
$35.7K
May 15, 2025
Q3
2024
Sep 30, 2023
$11.8K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$4.1K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$0
May 13, 2024
Q3
2023
Sep 30, 2022
$0
Nov 13, 2023
Q2
2023
Jun 30, 2022
$0
Aug 14, 2023
Q1
2023
Mar 31, 2022
$0
May 10, 2023
Q3
2022
Sep 30, 2021
$0
Nov 14, 2022
Q2
2022
Jun 30, 2021
$0
Aug 4, 2022
Q1
2022
Mar 31, 2021
$0
May 13, 2022
Q3
2021
Sep 30, 2020
$0
Apr 21, 2022
Q2
2021
Jun 30, 2020
$0
Aug 16, 2021
Q1
2021
Mar 31, 2020
$20.0K
May 17, 2021
Q3
2020
Sep 30, 2019
$0
Nov 12, 2020
Q2
2020
Jun 30, 2019
$0
Aug 13, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$65.6K
Nov 14, 2025
Q2
2025
Jun 30, 2025
$53.4K
Aug 14, 2025
Q1
2025
Mar 31, 2025
$0
May 15, 2025
Q3
2025
Sep 30, 2024
$31.5K
Nov 14, 2025
Q2
2025
Jun 30, 2024
$0
Aug 14, 2025
Q1
2025
Mar 31, 2024
$35.7K
May 15, 2025
Q3
2024
Sep 30, 2023
$11.8K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$4.1K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$0
May 13, 2024
Q3
2023
Sep 30, 2022
$0
Nov 13, 2023
Q2
2023
Jun 30, 2022
$0
Aug 14, 2023
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2013
Mar 31, 2013
$0
May 6, 2013
Q3
2012
Sep 30, 2012
$0
Nov 19, 2012
Q2
2012
Jun 30, 2012
$0
Aug 31, 2012
Q1
2012
Mar 31, 2012
$0
May 15, 2012
Q3
2011
Sep 30, 2011
$31.9K
Nov 21, 2011
Q2
2011
Jun 30, 2011
$24.1K
Sep 13, 2011
Q1
2012
Mar 31, 2011
$32.6K
May 15, 2012
Q3
2011
Sep 30, 2010
$19.3K
Nov 21, 2011
Q2
2011
Jun 30, 2010
$19.1K
Sep 13, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.03M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($1.64M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($4.21M)
May 15, 2025
Q3
2025
Sep 30, 2024
($2.27M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($8.24M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($1.28M)
May 15, 2025
Q3
2024
Sep 30, 2023
($1.82M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($2.07M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($1.97M)
May 13, 2024
Q3
2023
Sep 30, 2022
($2.00M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($2.07M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($2.03M)
May 10, 2023
Q3
2022
Sep 30, 2021
($1.55M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($1.85M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($2.22M)
May 13, 2022
Q3
2021
Sep 30, 2020
($3.50M)
Apr 21, 2022
Q2
2021
Jun 30, 2020
($1.17M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($2.54M)
May 17, 2021
Q3
2020
Sep 30, 2019
($1.78M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($2.54M)
Aug 13, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.02M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($1.63M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($4.21M)
May 15, 2025
Q3
2025
Sep 30, 2024
($2.26M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($8.23M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($1.28M)
May 15, 2025
Q3
2024
Sep 30, 2023
($1.57M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.82M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($1.97M)
May 13, 2024
Q3
2023
Sep 30, 2022
($2.00M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($2.07M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($2.03M)
May 10, 2023
Q3
2022
Sep 30, 2021
($1.67M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($1.75M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($2.08M)
May 13, 2022
Q3
2021
Sep 30, 2020
($3.36M)
Apr 21, 2022
Q2
2021
Jun 30, 2020
($1.03M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($2.41M)
May 17, 2021
Q3
2020
Sep 30, 2019
($1.57M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($2.04M)
Aug 13, 2020